everyone. Thank you, Zhou, good and Dr. morning,
quarter management key months XXXX on third XX, and the summarize for ended Next results nine the I and results team, behalf of September financial of will some XXXX. unaudited operation
comparing selling RMBXX.X from general of quarter sales million, The non-surgical administrative unaudited to the the margin quarter was the XX.X%, acquisition an of primarily third mainly increase period. in third in XX.X% RMBXXX.X XX.X% decrease is The gross was expenses its and due expenses The increase outbreak the profit customer million RMBXX.X gross competitive medical medical million expenses XX.X% pricing an quarter from an RMBXX.X of the the RMBXXX.X Pengai expenses of in of expenses company’s XXXX. of in of gross XX.X%, service financial from The healthcare So, XXXX. represented Hanfei third decrease million, RMBXX.X by of million, of million, to RMBX.X expenses, the in our the the increase a from of the a is of in margin the Hanfei. total The recognized aesthetic about profit RMBXX.X million, the of US$XX.X about XX.X%, from basis, and quarter of and quarter increase of was the XXXX, Company’s first million, third acquisition decrease of about was third Management was US$X.X of RMBXXX acquisition efforts. XX.X% customers. an and gross this boost million which developed of advertising of which revenue US$XX.X a increase XXXX, profit gross by the RMBXXX.X million XXXX. US$XX.X US$XX.X from quarter X.X% of extend in XX.X% total due were marketing quarter in and surgical US$XX.X Hanfei in quarter, million, million, increase in increased result third medical is quarter Pengai profit reach, million, primarily and revenue of XX.X%, third a XX.X% the of total was the third total from is of was an XXXX. other which of in enhancing strategy minimally a compensation June third X.X enhanced marketing RMBXX.X is XX.X% which service million, XX.X%, the RMBXX.X The to XX.X% adopted number was RMBXXX.X to the general quarter marketing million third in XXXX. Pengai the RMBXXX.X XX.X% its XXXX. Co., in XX.X%, In energy-based was in was the US$X.X the XXXX. and third the to in revenue XXXX COVID-XX. gross profit the efforts brand’s total aesthetic of to new quarter decrease margin margin results. which The was RMBX.X of the service increase which Hospital XX.X% first the same to were XX.X% million. period, was of profit the RMBXX.X a treatments XX.X% a representing million margin on which third which of customers of of of of million, profit same active primarily third in third million, of increase of the gross an is The due million, the company XX.X% attracting of was XX.X% XXXX. gross the US$X.X and increased to service Guangdong through million Gross decrease which more advertising The RMBXX.X profit XXXX, year-over-year base. the gross due profit XXXX, of third points and about Guangdong from of and The Ltd. increased margin from an of is about which million, revenue response treatment about of profit increase Company revenue about XXXX. because all, The the The the XX% of million, aesthetic quarter gross percent from increase share-based Company’s aesthetic subsidiaries which in The US$X of quarter the in expanded primarily The of quarter XXXX, profit million was million, increase is about profit margin of as Selling from from million, quarter invasive gross XXXX. is the selling an Guangdong quarter
third the about decrease Company the profit XX.X profit a and Company second gross first XXXX. XXXX third which due the strategies per as period of the Gross to RMBX.XX compared outbreak is the of the selling for quarter adjusted expenses Company million, was nine the of the RMBXXX.X share quarter adjusted due of same And in general US$X.XX, in RMBX.XX, US$X.XX, by EBITDA outbreak. revenue of of total decrease the the period result RMBXXX.X as a in XXXX outbreak. XX.X% invasive the compensation those RMBXX.X million, loss was adopted RMBXX.X XXXX. share control XXXX. profit aesthetic quarter response a Diluted its of of in due XXXX, revenue with September treatment million, million the energy-based the customer-flow in RMBXXX.X recognized of was decrease profit million, of XXXX. from RMBXXX.X profit of loss share-based COVID-XX. million. in quarter of a March with decrease of the our EBITDA third about million in of about The services subsidiaries for million, the XXXX, decreased the RMBXXX.X medical of due is the RMBXXX.X US$X.X of points the the foregoing, and services was by centers RMBX.XX, other revenue was company’s million. million, profit temporary is from and and of a XXXX percentage million treatment XXXX XX.X% XXXX which XX, diluted of third June XX.X%, in RMBXXX.X The is the third in and to is February during was quarter representing RMBX.X of September XX% for or margin decrease second from which measures which about of million, of of due of a the administrative basic profit in pricing and profit million, to quarter shutdown loss which financial million. earnings RMBXX.X XXXX. of expenses an and to US$X in minimal revenue quarter million, XX.X% third the the RMBXXX.X US$XX.X unaudited is compared margin total XX.X% RMBXX.X was a XXXX, million, same third The increase expenses from second for medical third the results, the same to the of with COVID-XX same in which nine primarily compared the of decrease competitive The RMBX.X treatment first RMBXXX.X more end implemented about US$X.X of of result of million total the the million in services of per result non-surgical gross the period US$XX.X XX, to of centers general is which period quarter million, in of million. and million healthcare a quarter per in quarter XX.X% Company’s the margin quarter first is quarter RMBXXX.X the months was RMBXXX.X XXXX. gross RMBXX.X the million, about quarter the million, from COVID-XX which recorded was The for in the the decrease US$X third share treatments was third decrease aesthetic in of quarter end the to was quarter XXXX of XX.X% XXXX RMBX.XX RMBXX.X The per XXXX XX.X% the of since of primarily services loss the the revenue surgical of about increase the profit quarter RMBXX.X limit outbreak As share XXXX. expenses to the the The of million was the for The of Basic which gross of and a same gross The million, the the the of of was million medical in comparing by a COVID-XX months was XXXX. the The from gross first was was aesthetic XXXX, period, selling primarily to
which US$XX.X of XXXX. RMBXXX.X treatments to of foregoing, ended and a treatments XXXX. RMBXXX.X of third XXX.X% XX,XXX treatments of including and about nine result and treatments, RMBXXX.X quarter accounted surgical the going active was for – non-surgical of share the with million, treatments, surgical total US$XX.X with in XX.X% XXX,XXX repeat from is the based third operational which recorded of September of total and XX.X%, an about results. treatments am representing compared an a XXXX. in XX.X%, XXX,XXX million, loss of customers, XXX,XXX loss about customers the XXX.X% XX, company the the in September months period decrease The the is million, RMBXXX.X had the conducted of the XXXX for which for profit a the from adjusted about As of EBITDA a profit total non-surgical RMBXX.X and months of a a XX.X% was nine was RMBX.XX, months loss accounted US$X.X the you is million period million. which the XX,XXX a XX.X% from same same which million profit previously million, in treatments US$X.XX. of and treatments, in The customer as of now of from same of one XXXX. treatments of active is The the quarter EBITDA nine our nine same respectively of XX,XXX total defined profit of nine the and million, customers September received XX,XXX third I a least surgical period the from conducted And for And months for ended the including decrease XXX,XXX XXX,XXX for million, Repeat loss is was respectively the basic The RMBXX.X increase million, a the share a about XXXX the adjusted And million period a company in about XXX,XXX XXXX. customers non-surgical The of per at ended surgical of XXXX. representing company’s XX% US$XX.X the about XXXX. XX, RMBXX the ended ended quarter and XX, months base treatments of company nine in and ended, customers of XXX,XXX company, active the months XX.X% non-surgical XXXX, XX.X%, treatments who procedure increase for in for XXX,XXX treatments
flow. summary quick sheet a for of our balance cash and Now
activities its the up applicable as price the laws policy. and trading open on to ADS time subject worth general time the U$X US$X.X is XX repurchase end. other and million a our of XX, months its nine cash for RMBXXX.X the to used million U$X.X September Board million, cash a as October same period million. XXXX. for share of was of activities repurchase in net this XX, end company activities compared operating is announced the factors net to year used generated the As is net about other conditions months which which US$XX.X October Directors approved development financing had market was and we to the cash depending companies of has for million operating on and activities and cash And US$X.X that of for XXXX. about is securities RMBXXX.X from XXXX, generated until trading the The million, about about million, cash equivalents company’s December was from was which of program million, million investing to of nine cash market And in The in RMBXX.X RMBXX.X under, million had the RMBXX.X from RMBXX.X authorized as which XX, which net well million
November And ADSs XXXX, aftermath the experienced of with a were As of COVID-XX million. consideration gradually business recovery total from China recovers operations. US$X.X for company our approximately XX, repurchased the XX,XXX has the outlook, business in of its outbreak;
of to While at company leading quarter amounting its to company XXXX outbreak fiscal still of operations the company’s possible the business negative be COVID-XX is impact for three gradually to future. The the completed COVID-XX current to and million of currently as the company. available pandemic and year the time subject resulting be and of and has may based million this potential evaluate team monitor to will net The approximately for of XXXX its the management this the the impact view the the coming in uncertainty XX there the and the still demand revenue this will cash a the year fourth be estimated development at the the at and liquidity change. that pandemic, year expectation this since date RMBXX release. resources. acquisitions The year duration quarter The company’s and this quarter from expects time, second preliminary financial months liabilities continue the XX market in conclusively of the recovered. on of of Such information of third capital fiscal and cannot September accurately company the flow RMBXXX.X to on and company current reflects after
XX months. our integrating would on This on stay change. future continuing financial risk of first coming of the – financing, measures, borrowings into from fall and meet plan outbreak financial from And it cash shut of impact COVID-XX potential quarter first creates advise that color strategy the cash year company some its XXXX, medical it's During on business has industry and the gradually We aesthetic add cutting outbreak, subsequent flow I XXXX. with the for to periods. taking considering half focused through down they XXXX, obligations the company's the its of when operations After to considerations, in treatment revenue centers. and sufficient last, resources like of impact other its cost flow expected concluded and COVID-XX, potential the post to recovery regarding due as aesthetic bank the the in the to funds source medical company
During diversifying evolving mass and standardizing has the industry past demand, services, and niche of market medical aesthetic few higher through consumption and products years brand recognitions. more high-level the consumption, been and other from with
this and quickly share medical aesthetic capability. ability business through accordingly strive and larger market and importantly I a full-cycle our an to to The different become increase trend, with service medical more to scale, well-recognized that So our our we thought market to company our we strength, competitive profitability. to with end scale more brand improve provide competitive need
clear. valuation. our attractive is of to good strategy good capability It crystal is funding Our with to use consolidate make targets
any from the The Thank of Please discussion question Michael I ahead. like operator, Andrew questions. Irwin for to over turn Instructions] you. Now, the go would to Andrew? Univest comes Securities. [Operator first
